Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248404 · ClinicalTrials.gov registry record · Phase 1
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
A Phase 1 study of Tumors, sponsored by Kiadis Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
- 3
- Study locations
NCT00248404: Completed Phase 1 study of Tumors, sponsored by Kiadis Pharma.
NCT00248404 is a Phase 1 study of Tumors that has completed, run by Kiadis Pharma. The registered enrollment target is 155 participants, below the 192-participant average among 20 other Tumors trials with a reported enrollment target (19% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248404, a Phase 1 study of Tumors, has completed, sponsored by Kiadis Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Conditions Studied
Interventions
- DRUG NB1011
Study Locations (3)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Minnesota
- University of Minnesota - Minneapolis
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12-12 |
| Phase | Phase 1 |
What the finished NCT00248404 record still lists
NCT00248404 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 20 other Tumors trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which NB1011 is the first listed.
NCT00248404 reports a single indexed study location in California, Minnesota, Ontario.
Frequently Asked Questions
What is clinical trial NCT00248404 about?
NCT00248404 is a clinical study titled "NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)". The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
What is the current status of trial NCT00248404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2005-09. Estimated completion is 2007-12-12.
What conditions does trial NCT00248404 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00248404?
The interventions under investigation include: NB1011 (DRUG).
Who is sponsoring clinical trial NCT00248404?
This trial is sponsored by Kiadis Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248404 being conducted?
This trial has 3 study locations across California, Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00248404's enrollment target sits among peer trials
155 6th of 20 higher than 15 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia